• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Genotype 3-hepatitis C virus' last line of defense

    2021-04-01 09:13:16DorotaZarebskaMichaluk
    World Journal of Gastroenterology 2021年11期

    Dorota Zarebska-Michaluk

    Abstract Chronic infection with hepatitis C virus (HCV) is one of the leading causes of liver disease globally, affecting approximately 71 million people. The majority of them are infected with genotype (GT) 1 but infections with GT3 are second in frequency. For many years, GT3 was considered to be less pathogenic compared to other GTs in the HCV family due to its favorable response to interferon (IFN)-based regimen. However, the growing evidence of a higher rate of steatosis, more rapid progression of liver fibrosis, and lower efficacy of antiviral treatment compared to infection with other HCV GTs has changed this conviction. This review presents the specifics of the course of GT3 infection and the development of therapeutic options for GT3-infected patients in the era of direct-acting antivirals (DAA). The way from a standard of care therapy with pegylated IFNalpha (pegIFNα) and ribavirin (RBV) through a triple combination of pegIFNα + RBV and DAA to the highly potent IFN-free pangenotypic DAA regimens is discussed along with some treatment options which appeared to be dead ends. Although the implementation of highly effective pangenotypic regimens is the most recent stage of revolution in the treatment of GT3 infection, there is still room for improvement, especially in patients with liver cirrhosis and those who fail to respond to DAA therapies, particularly those containing inhibitors of HCV nonstructural protein 5A.

    Key Words: Hepatitis C virus; Genotype 3; Antiviral treatment; Interferon; Direct-acting antivirals; Pangenotypic

    INTRODUCTION

    Chronic infection with hepatitis C virus (HCV) is assumed to be one of the leading causes of liver disease globally, affecting approximately 71 million people[1]. Due to the high genetic diversity of the viral nucleic acid sequence, six major genotypes (GT), differing from each other by 30% at the nucleotide level, comprising multiple subtypes of HCV, have been identified[2]. The majority of patients worldwide are infected with GT1, but infections of GT3 are also common in some regions. GT3 is defined by a higher rate of steatosis, increased risk of liver cirrhosis, and different response to antiviral drugs compared to other GTs. In the era of treatment with pegylated interferon alpha (IFNα) and ribavirin (RBV), patients infected with GT3 were considered "easy to treat" due to an efficacy rate of 70%, compared to less than 50% in GT1 and GT4 infected patients. The introduction of direct-acting antivirals (DAA) has changed the management of HCV infection, allowing a substantial increase in the treatment efficacy, however, the improvement for GT3 infection was not as pronounced as for other GTs, particularly in treatment-experienced patients and those with liver cirrhosis.

    THE GLOBAL SPREAD OF GT3

    GT3 infections are widely distributed worldwide and are estimated to be the second in frequency accounting for approximately 25%-30% of all HCV cases globally[2]. The distribution of GT3 varies between different countries and continents. The highest global prevalence (exceeding 70%) is found in South Asian countries, while a rate of approximately 20% is reported in Central and Southeast Asia, a few percent in East Asia, and only 0.4% in the Asia-Pacific region. A relatively high frequency of 36% is documented in Australia[3]. GT3 infection accounts for 14.2% of HCV cases in South America, 2.1% in Central America, and 15.7% in North America, ranging from 8.9% in the United States to 22.3% in Canada[3]. In Europe, the distribution of GT3 infections is also heterogeneous with the highest frequency exceeding 40% in Scandinavia and England, over 30% in Ireland, Greece Russia, and Slovenia, and more than 20% of infections in Germany, Switzerland, Montenegro, Belgium, Bosnia, and France[4-6]. The rate of a dozen percent is reported from Spain, Poland, Portugal, Bulgaria, and Croatia, whereas the lowest prevalence, below 10%, are documented in Italy, Albania, Hungary, and Romania[7-10]. The lowest proportional frequency of GT3 infections is found in Africa at an average of 5.3%, with the highest frequency at 7.4% in East Africa through 6.3% in North Africa to 0.8% in the central part of the continent[3].

    GOOD OR BAD IN THE HCV FAMILY

    For many years, GT3 was considered to be less pathogenic compared to other GTs in the HCV family due to its favorable response to an IFN-based regimen. However, the growing evidence of a higher rate of steatosis and more rapid progression of liver fibrosis compared to infection with other HCV GTs has changed this conviction.

    Liver steatosis is a frequent histological finding in patients with chronic hepatitis C (CHC). Although this feature is common among all HCV infected individuals, with an average rate of 50%, the highest prevalence exceeding 70% is observed in patients infected with GT3[11-14]. In in-vitro studies, GT3 is also demonstrated to be much more likely to induce liver steatosis than other HCV GTs[15]. The pathogenesis of hepatic steatosis is complex and related to host and viral factors, as well as to alcohol consumption. Metabolic steatosis, which is associated with host risk factors including high body mass index, obesity, dyslipidemia, metabolic syndrome, insulin resistance and type 2 diabetes, is commonly found in patients infected with non-GT3 HCV, whereas in the GT3-infected individuals, virus-related hepatic steatosis is described as predominantly being induced by the direct cytopathic effect of the HCV[16-20]. Although the exact mechanism remains unknown, several pathways are linked to the pathogenesis of GT3-induced steatosis. A central role is played by the inhibition of microsomal triglyceride transfer protein function by HCV core protein, resulting in overall decreased hepatocyte lipid export with intracellular triglycerides accumulation. This effect is documented to be amplified with HCV-3 core proteins[21]. Another mechanism through which the virus modulates the host lipid metabolic pathways is inhibition of the peroxisome proliferator associated receptor-α (PPAR-α), a transcription factor inducing hepatic fatty acid oxidation and ketogenesis. A decrease in PPAR-α level leads to hepatic lipid collection. In vitro studies document inhibition of PPAR-α observed in the GT3 infections as being more efficient than in infections with GT1 HCV[22]. Viral-induced hepatic steatosis results not only from the reduction of the lipid excretion with subsequent intracellular lipid accumulation but also from the promotion of the neolipogenesis with fatty acid synthesis. This activity is proposed to be a consequence of an increase in function of sterol regulatory element-binding protein-1c activated by the HCV-3 core protein, however, the exact mode of activation is unknown[23]. The hypothesis of a pathogenic link between GT3 infection and steatosis is supported by a significant correlation of the steatosis score and intrahepatic titer of HCV RNA only in patients infected with GT3[16]. The improvement in liver steatosis in GT3-infected patients after successful antiviral therapy, which is not observed in patients infected with GT1, seems to indirectly confirm this association[24,25]. GT3 HCV was also identified as an independent predictor for the accelerated progression of liver fibrosis in addition to established risk factors including the age of infection, male gender, coinfection with hepatitis B virus and human immunodeficiency virus, insulin resistance, iron overload, alcohol and drugs intake[26]. Precise analysis of the influence of HCV GT on the more advanced liver disease is difficult due to the coexistence of the aforementioned predictors and the previously discussed higher prevalence of liver steatosis in GT3 infection, which contributes to more rapid progression of hepatic fibrosis[12,27,28]. However, the pooled analysis con?rmed a signi?cantly more severe liver disease in single-biopsy studies and a trend towards the faster progression of fibrosis in GT3 patients compared with the other GTs[29]. The strong association between GT3 infection and end-stage liver disease was documented in HCV-infected drug abusers in France and confirmed by a populationbased study in a cohort of native Alaskans with CHC[30,31].

    An increased risk not only of liver cirrhosis but also of hepatocellular carcinoma (HCC) among GT3 infected individuals compared to those infected with other GTs was reported in a large cohort (> 110000) of American patients from the Veterans Affairs Registry[32,33]. Consistent results of significantly higher incidence of HCC in GT3 patients were also obtained in French and Korean populations[34,35]. Nevertheless, the effect of HCV GT3 infection on the higher prevalence of liver cancer remains controversial because of the data demonstrated for GT1b as a major risk factor for HCC development[36,37].

    IFN AND RBV COUPLE

    The standard of care therapy of pegylated (peg) IFNα and RBV established in 2000 has resulted in a sustained virologic response (SVR) of approximately 70% in GT3-infected patients[38-42]. Such a high effectiveness compared to the SVR below 50% achieved by patients with GT1 and GT4 infection was the basis for the GT3 being deemed "easy to treat" and has led to attempts to shorten the treatment course to 16, 14, and even 12 wk. However, the reduction in the SVR rate was reported in patients who did not achieve the so-called rapid virologic response (RVR) defined as undetectability of HCV RNA after 4 wk of therapy[38,39,42-44]. The meta-analysis of twelve clinical trials performed by Andriulli et al[45]documented a wide variance in response to pegIFNα and RBV in GT3-infected patients depending on the baseline viral load. Individuals with a high baseline level of HCV RNA demonstrated a significantly lower SVR rate of 58% compared to 75% in those with a low baseline viral load. The strongest predictive factor for treatment response was RVR and this finding provided the basis for the conclusion that patients without RVR may need a longer therapy duration. The negative impact of cirrhosis on treatment response among subjects infected with GT3, leading to poor antiviral effectiveness was documented by Powis et al[46], suggesting that such patients also require an alternative management strategy. However, the extension of the treatment course did not result in higher effectiveness, nor was there an improvement in the SVR rate on increasing the dose of RBV[47-49].

    THE COUPLE WITH A LITTLE HELP OF DAA

    The registration of the first DAAs in 2011, which were inhibitors of the HCV serine protease (nonstructural protein 3/4A, NS3/4A), started a revolution in the treatment of CHC. The combination of telaprevir or boceprevir with pegIFNα and RBV significantly increased the SVR rate, but only in patients infected with GT1[50,51]. Those infected with other GTs, including GT3, were still treated with pegIFNα and RBV because no significant improvement was demonstrated after the addition of telaprevir or boceprevir[52,53]. Therefore, at the beginning of the DAA era GT3 emerged as a "difficult-to-treat" GT. New hopes for higher effectiveness were raised with the introduction of the next-generation DAAs for possible combination with pegIFNα and RBV. Unfortunately, clinical trials demonstrated that simeprevir, a second-wave protease inhibitor with documented in-vitro pangenotypic activity has limited efficacy in GT3-infected patients, and the effectiveness of daclatasvir (DCV), acting through inhibition of the HCV nonstructural protein 5A (NS5A), has proven to be also disappointing, with SVR rates of 45% and 74% in GT3 patients with and without liver cirrhosis, respectively[54,55]. However, the expectations of a higher response rate among GT3-infected patients have been met by sofosbuvir (SOF), a new DAA class representative, HCV polymerase (NS5B) inhibitor. The addition of SOF to pegIFNα and RBV (SPR) leads to better outcomes when compared to standard of care therapy, regardless of liver fibrosis and history of previous antiviral therapy. Phase 2 clinical trials documented a response of 83% among treatment-experienced patients with liver cirrhosis participating in the LONESTAR-2 study, while non-cirrhotic, treatment-na?ve individuals treated in the QUANTUM study responded in 92% of cases[56,57].

    Patients included in the BOSON phase 3 clinical trial achieved an SVR of 93%, specifically 88% among individuals with liver cirrhosis and 95% in those without; the lowest efficacy of 86% was demonstrated for patients with liver cirrhosis who failed to respond to previous antiviral therapy[58]. An open-label clinical study evaluating the outcome of SOF-containing treatments reported 100% efficacy among GT3-infected treatment na?ve patients without cirrhosis treated with triple therapy[59].

    Those results from clinical trials were supported by real-world experience (RWE) data that documented an SVR rate higher than that following dual therapy. The best response of 93% was reported for non-cirrhotics among Americans treated in the Veterans Affairs health care system[60]. Scandinavian patients responded in 96% of cases, an efficacy of 98% was obtained in the Polish EpiTer-2 study and an SVR reached 99% in a German cohort[6,61,62]. The effectiveness of the SPR regimen in cirrhotic individuals in these RWE studies was also promising, reaching 92%, 81%, 91%, and 88%, respectively[6,60-62].

    RWE data revealed a failure of previous therapy, with a history of treatment with IFN and RBV shown to be a negative prognostic factor of the response to SPR treatment. This triple regimen was still recommended by the guidelines of the European Association for the Study of the Liver in 2015 for GT3-infected non-cirrhotic patients and those with compensated liver cirrhosis, regardless of treatment history[63]. Irrespective of the high effectiveness of SPR, accompanied by reasonable tolerability due to the short treatment period, any IFN-based therapy was refused by patients[61]. Therefore, further research on the treatment of GT3 infections has focused on highly efficient IFN-free therapeutic options.

    DAA HOME ALONE

    The first available IFN-free regimen, SOF and RBV, used in GT3-infected patients for 12 wk or 16 wk, did not result in increased efficacy when compared to standard of care therapy, which demonstrated significantly lower response rates in patients with liver cirrhosis, especially in those who had previously failed IFN and RBV therapy (Table 1)[40,58,64].

    The extension of treatment duration to 24 wk enabled effectiveness of up to 95%,however, the difference in response rates between patients without and with liver cirrhosis was significant[58,65]. The results of phase 3 clinical trials confirmed by RWE data became a basis for treatment guidelines, according to which IFN-ineligible GT3-infected patients should receive SOF/RBV for 24 wk. However, this regimen was recognized as suboptimal, due to unsatisfactory effectiveness for those with liver cirrhosis who had previously failed IFN and RBV therapy[66-68].

    Table 1 Efficacy of interferon-free regimens in genotype 3 patients in clinical trials

    1NS5A-inhibitor-experienced.2No detailed information on the response rate in patients with and without liver cirrhosis.3Recommended by American Association for the Study of Liver Diseases/Infectious Diseases Society of America as an alternative option for pegylated interferon + ribavirin-experienced patients with compensated liver cirrhosis. SVR: Sustained virologic response; GT: Genotype; SOF: Sofosbuvir; RVB: Ribavirin; DCV: Daclatasvir; VEL: Velpatasvir; VOX: Voxilaprevir; GLE: Glecaprevir; PIB: Pibrentasvir; LDV: Ledipasvir; ALV: Alisporivir; OBV: Ombitasvir; PTV/r: Paritaprevir boosted by ritonavir; GZR: Grazoprevir; EBR: Elbasvir; UPR: Uprifosbuvir; RBV: Ribavirin; RZR: Ruzasvir.

    Searching for the optimal antiviral regimen, the combinations of SOF and another DAA with a different mechanism of action were studied. Promising results were obtained with a SOF and DCV combination administered for 12 wk and 24 wk, with or without RBV[69-71]. Although the difference in response rates with SOF + DCV ± RBV between non-cirrhotic and cirrhotic patients was still noticeable, this regimen was recommended for the treatment for GT3-infected patients regardless of liver fibrosis and history of previous therapy and has been widely used in RWE settings[66,72-74]. High efficacy and good tolerability demonstrated in both clinical trials and real-world cohorts have made this regimen a reasonable choice for therapy for GT3 infection as long as highly potent pangenotypic options became broadly available[75-77].

    BETTER IS THE ENEMY OF GOOD ENOUGH

    The final stage of the revolution in antiviral treatment which improved the outcome and simplified the management of GT3-infected patients was the implementation of potent pangenotypic regimens (Table 1).

    According to the most recent guidelines, two basic options of DAAs are currently approved for the treatment of GT3 infection; a fixed-dose combination of SOF and velpatasvir (VEL), and dual treatment with glecaprevir (GLE), an NS3/4A protease inhibitor, and pibrentasvir (PIB), an NS5A inhibitor (Table 2)[78,79]. A single-tablet regimen containing SOF and VEL was registered based on the results of the ASTRAL-3 study, which confirmed effectiveness exceeding 93% in non-cirrhotic and 89% in cirrhotic patients[80]. The 12-wk regimen is recommended for non-cirrhotics and patients with compensated cirrhosis, regardless of the previous treatment history. The addition of RBV may be considered in compensated individuals.

    It is noteworthy that SOF/VEL combined with RBV is the only option recommended for patients with decompensated liver cirrhosis[81,82]. Data on the high efficacy and favorable safety profile of SOF/VEL achieved in clinical trials were supported by RWE studies reporting comparable SVR rates. Prior treatment-experience, as well as advanced liver fibrosis, were significant predictors of reduced effectiveness[83-87]. As resistance-associated substitutions at the NS5A position can be responsible for a reduction in the efficacy of the NS5A inhibitors, the resistance-associated substitutions testing at baseline should be considered for treatment-experienced patients and cirrhotic individuals, irrespective of treatment history, for whom SOF/VEL is being considered. The identification of the Y93H substitution indicates the need for RBV addition or an alternative regimen administration[78,79].

    The second potent pangenotypic option is a combination of GLE and PIB, which was approved for the treatment of patients without or with liver cirrhosis irrespective of previous therapy. As protease inhibitors containing regimens carry a risk of decompensation during antiviral treatment, GLE/PIB is not recommended for decompensated cirrhotic patients[88]. This regimen provides the opportunity for shortening therapy to 8 wk in the majority of patients[89]. Based on findings from the ENDURANCE-3, SURVEYOR-II, and EXPEDITION-8 clinical trials, an 8-wk regimen has been registered for all previously untreated patients, including those with compensated liver cirrhosis, whereas treatment-experienced GT3-infected individuals should be treated for 16 wk regardless of liver fibrosis[90-94]. RWE studies reported effectiveness for an 8-wk GLE/PIB regimen, which exceeded 96% in treatment-na?ve patients without liver cirrhosis[95-99]. Since the shortening of therapy in previously untreated cirrhotic patients infected with GT3 has been approved very recently, the available RWE data are very limited and only include a small number of patients[100,101]. Therefore, further studies are needed to determine the treatment outcome in this subpopulation. Although the implementation of SOF/VEL and GLE/PIB regimens has resulted in a high efficacy rate among GT3-infected individuals, there is still room for improvement, especially in those who did not achieve SVR, particularly following NS5A containing regimens. For such patients, a 12-wk salvage therapy with a singletablet combination of SOF/VEL and next-generation NS3/4A protease inhibitor voxilaprevir (VOX) is recommended[102]. Safety and efficacy of SOF/VEL/VOX in GT3-infected patients without and with liver cirrhosis, both treatment-na?ve and treatmentexperienced were demonstrated in the POLARIS studies (Table 1)[102,103].

    The other option to address failed DAA treatment in GT3-infected patients is a combination of GLE/PIB plus SOF and RBV, as investigated in the MAGELLAN-3 study. This demonstrated a 100% SVR rate, however, the small number of patients enrolled may have limited the broad applicability of these findings[104].

    SOMETHING WENT WRONG

    On the way to developing highly effective pangenotypic regimens against GT3, there were multiple paths that appeared to be dead ends. Some of them were not investigated despite showing encouraging initial results, due to disappointing treatment outcomes in selected subpopulations of GT3 patients. One good example is an open-label study of 12-wk treatment with an NS5A inhibitor—ledipasvir and SOF, plus RBV, which demonstrated a 100% SVR rate among treatment-na?ve GT3 infected individuals. Unfortunately, due to limited efficacy in treatment-experienced patients, especially those with liver cirrhosis, as well as low antiviral potency without RBV against GT3, that direction of search has proved a blind alley[105]. Alisporivir, a cyclophilin inhibitor, applied alone or with RBV in treatment-na?ve non-cirrhotic patients has resulted in SVR rates of 76% and 93%, respectively, however, research involving other subgroups of patients was suspended due to a safety issue[106]. Efficacy was observed to be below expectations with the combination of the NS3/4A inhibitor grazoprevir (GZR) and the NS5A inhibitor elbasvir (EBR) with RBV, as well as with a regimen consisting of the NS5A inhibitor ruzasvir and the NS5B inhibitor uprifosbuvir[107,108]. The unsatisfactory outcome of the treatment with NS35A inhibitor ombitasvir, and NS3/4A inhibitor paritaprevir boosted by ritonavir with or without RBV, was subsequently improved by the addition of SOF, but ultimately these regimens were not further evaluated, because there were new potent pangenotypic options on the horizon[109,110]. For this same reason, investigations into a regimen of GZR/EBR combined with uprifosbuvir or SOF were discontinued, despite the high effectiveness demonstrated in phase 2 clinical trials. However, GZR/EBR + SOF is currently recommended by AASLD/IDSA as an alternative option for the specific subpopulation of pegIFNα+RBV-experienced patients with compensated liver cirrhosis[79,111-113].

    Table 2 European Association for the Study of the Liver and American Association for the Study of Liver Diseases/Infectious Diseases Society of America current recommendations on the treatment of genotype 3-infected patients

    CONCLUSION

    Despite the high efficacy and safety of pangenotypic therapies, that may sooner or later cure all or at least almost all identified HCV infections, including GT3, there will still be many infections that go unrecognized and are therefore impossible to cure with even the best drug. The major problem that remains to be solved worldwide is screening people who are unaware of the risk of liver disease progression from a virus in their body. It is a shame for national governments that, despite having access to the perfect tool to eliminate a dangerous virus and rule out one of the most difficult-totreat cancers, are not doing enough.

    国产成人精品久久久久久| 国产男人的电影天堂91| 少妇被粗大猛烈的视频| 少妇被粗大猛烈的视频| 久久久久久伊人网av| 日韩人妻高清精品专区| 久久久午夜欧美精品| 美女大奶头视频| 日本欧美国产在线视频| 性插视频无遮挡在线免费观看| 亚洲精品久久国产高清桃花| 麻豆国产av国片精品| 国产精品人妻久久久久久| 伊人久久精品亚洲午夜| 白带黄色成豆腐渣| 日本五十路高清| 免费电影在线观看免费观看| 免费观看a级毛片全部| 亚洲国产精品sss在线观看| 国产午夜福利久久久久久| 国产免费男女视频| 午夜福利在线观看吧| 久久久久久大精品| 国产黄片视频在线免费观看| 亚洲高清免费不卡视频| 亚洲高清免费不卡视频| av女优亚洲男人天堂| 可以在线观看的亚洲视频| 亚洲人与动物交配视频| 日本av手机在线免费观看| 国产精品人妻久久久影院| 亚洲精品粉嫩美女一区| 国产精品人妻久久久影院| 人人妻人人澡人人爽人人夜夜 | 日韩人妻高清精品专区| av又黄又爽大尺度在线免费看 | 久久99精品国语久久久| 国产乱人视频| 在线免费观看的www视频| 激情 狠狠 欧美| 亚洲av熟女| 性欧美人与动物交配| 国产综合懂色| 久久久久免费精品人妻一区二区| 亚洲精品亚洲一区二区| 一区福利在线观看| 久久久久久久午夜电影| 国产黄色视频一区二区在线观看 | 亚洲第一电影网av| 亚洲av不卡在线观看| 伊人久久精品亚洲午夜| 亚洲成人久久性| 亚洲精品乱码久久久久久按摩| 国产精品av视频在线免费观看| 亚洲精品粉嫩美女一区| 观看美女的网站| 又爽又黄无遮挡网站| 丝袜喷水一区| 日韩欧美在线乱码| 国产极品天堂在线| 亚洲综合色惰| 美女黄网站色视频| 99在线人妻在线中文字幕| 久久久久九九精品影院| 成熟少妇高潮喷水视频| 国产在视频线在精品| 亚洲无线观看免费| 亚洲国产高清在线一区二区三| 此物有八面人人有两片| 嫩草影院精品99| 99riav亚洲国产免费| 国产成人a∨麻豆精品| 成熟少妇高潮喷水视频| 看黄色毛片网站| .国产精品久久| 日韩欧美 国产精品| 日韩精品有码人妻一区| 久久久精品欧美日韩精品| 成人av在线播放网站| 国产乱人偷精品视频| 亚洲欧美成人精品一区二区| 国产精品久久久久久亚洲av鲁大| 国产精品,欧美在线| 免费电影在线观看免费观看| 少妇裸体淫交视频免费看高清| 国产亚洲欧美98| 啦啦啦观看免费观看视频高清| 日韩,欧美,国产一区二区三区 | 男人舔女人下体高潮全视频| 久久精品综合一区二区三区| 免费看美女性在线毛片视频| 免费看av在线观看网站| 中文字幕久久专区| 成人高潮视频无遮挡免费网站| 26uuu在线亚洲综合色| 久久草成人影院| 男人狂女人下面高潮的视频| 如何舔出高潮| 大又大粗又爽又黄少妇毛片口| 国产美女午夜福利| 国产精品久久视频播放| 亚洲欧美清纯卡通| 久久午夜亚洲精品久久| 国产精品女同一区二区软件| 天美传媒精品一区二区| 我要看日韩黄色一级片| 99久久中文字幕三级久久日本| 爱豆传媒免费全集在线观看| 久久欧美精品欧美久久欧美| 美女内射精品一级片tv| 久久久久久久亚洲中文字幕| 久久99精品国语久久久| 久久午夜亚洲精品久久| 日韩精品有码人妻一区| 国内精品久久久久精免费| 久久精品国产亚洲av涩爱 | 亚洲av不卡在线观看| 欧美高清性xxxxhd video| 天堂中文最新版在线下载 | 亚洲,欧美,日韩| 成人av在线播放网站| 色尼玛亚洲综合影院| eeuss影院久久| 麻豆久久精品国产亚洲av| 欧美另类亚洲清纯唯美| 一个人观看的视频www高清免费观看| 久久久久久久久大av| 中文字幕人妻熟人妻熟丝袜美| 欧美bdsm另类| 亚洲欧美成人精品一区二区| 三级毛片av免费| 一级毛片久久久久久久久女| 亚洲欧美精品专区久久| 午夜爱爱视频在线播放| 中文字幕人妻熟人妻熟丝袜美| www.色视频.com| av天堂中文字幕网| 欧洲精品卡2卡3卡4卡5卡区| 欧美日韩在线观看h| 久久久久久大精品| 亚洲av不卡在线观看| 少妇裸体淫交视频免费看高清| 成人三级黄色视频| 精品一区二区三区人妻视频| 成熟少妇高潮喷水视频| 欧美变态另类bdsm刘玥| 在现免费观看毛片| 国产高清视频在线观看网站| 村上凉子中文字幕在线| 成人美女网站在线观看视频| 插阴视频在线观看视频| 黄片无遮挡物在线观看| 久久久久免费精品人妻一区二区| 精品99又大又爽又粗少妇毛片| 能在线免费观看的黄片| 可以在线观看的亚洲视频| 亚洲自偷自拍三级| 国内少妇人妻偷人精品xxx网站| 精品国内亚洲2022精品成人| 少妇人妻精品综合一区二区 | 日韩av不卡免费在线播放| 免费一级毛片在线播放高清视频| 婷婷色av中文字幕| 在线观看午夜福利视频| 一本—道久久a久久精品蜜桃钙片 精品乱码久久久久久99久播 | 亚洲最大成人手机在线| 有码 亚洲区| 亚洲乱码一区二区免费版| 大又大粗又爽又黄少妇毛片口| 精品日产1卡2卡| 在线免费十八禁| 日韩欧美精品免费久久| 日韩av不卡免费在线播放| 亚洲国产日韩欧美精品在线观看| 亚洲人成网站高清观看| av在线老鸭窝| 国产综合懂色| 精品人妻一区二区三区麻豆| 亚洲国产色片| 成人无遮挡网站| 美女内射精品一级片tv| 欧美zozozo另类| 免费看a级黄色片| av又黄又爽大尺度在线免费看 | 色哟哟哟哟哟哟| 看免费成人av毛片| 亚洲第一电影网av| 夜夜夜夜夜久久久久| 欧美极品一区二区三区四区| 99riav亚洲国产免费| 岛国在线免费视频观看| 菩萨蛮人人尽说江南好唐韦庄 | 国产精品电影一区二区三区| 成人综合一区亚洲| or卡值多少钱| 国产不卡一卡二| 在线观看av片永久免费下载| 国产成人freesex在线| 少妇猛男粗大的猛烈进出视频 | 午夜福利视频1000在线观看| 又粗又硬又长又爽又黄的视频 | 最新中文字幕久久久久| 网址你懂的国产日韩在线| 免费观看精品视频网站| 女的被弄到高潮叫床怎么办| 国产黄a三级三级三级人| 天天躁夜夜躁狠狠久久av| 国产免费男女视频| 成人毛片60女人毛片免费| 婷婷色av中文字幕| 女人被狂操c到高潮| 国产一级毛片在线| av黄色大香蕉| 日韩视频在线欧美| 亚洲精华国产精华液的使用体验 | 日韩视频在线欧美| 亚洲最大成人中文| 日韩高清综合在线| 天天躁日日操中文字幕| 精品午夜福利在线看| 在线观看一区二区三区| 精品国产三级普通话版| 波多野结衣高清无吗| 高清午夜精品一区二区三区 | 亚洲在久久综合| 亚洲性久久影院| 国产精品不卡视频一区二区| 国产精品电影一区二区三区| 免费搜索国产男女视频| 色哟哟·www| 欧美性猛交黑人性爽| 综合色av麻豆| 天堂√8在线中文| 久久久久久久午夜电影| АⅤ资源中文在线天堂| АⅤ资源中文在线天堂| 久久久精品94久久精品| 麻豆国产97在线/欧美| 久久中文看片网| 91久久精品国产一区二区三区| 欧美成人a在线观看| 可以在线观看的亚洲视频| 午夜激情欧美在线| 九色成人免费人妻av| 天堂√8在线中文| 18禁在线播放成人免费| 亚洲av第一区精品v没综合| 国产一区二区三区在线臀色熟女| 日韩精品青青久久久久久| a级一级毛片免费在线观看| 国产亚洲av片在线观看秒播厂 | 波野结衣二区三区在线| 精品少妇黑人巨大在线播放 | 亚洲五月天丁香| 黄色一级大片看看| 亚洲国产精品成人综合色| 免费看美女性在线毛片视频| 99九九线精品视频在线观看视频| 久久久久久国产a免费观看| 久久这里只有精品中国| 26uuu在线亚洲综合色| 精华霜和精华液先用哪个| av天堂在线播放| 国产精品福利在线免费观看| 成人国产麻豆网| 久久热精品热| 亚洲激情五月婷婷啪啪| 边亲边吃奶的免费视频| 男的添女的下面高潮视频| 久久精品人妻少妇| 国产真实伦视频高清在线观看| 久久久久久久久大av| 亚洲av一区综合| 久久人人爽人人爽人人片va| 久久久久久伊人网av| 九九热线精品视视频播放| av在线播放精品| 国产亚洲精品久久久com| 永久网站在线| 看黄色毛片网站| 波野结衣二区三区在线| 日本-黄色视频高清免费观看| 别揉我奶头 嗯啊视频| 51国产日韩欧美| 免费看日本二区| 亚洲无线观看免费| 国产不卡一卡二| 国产成人影院久久av| 国内精品久久久久精免费| 国产成人精品久久久久久| 精品久久久久久久久av| 三级毛片av免费| 天堂av国产一区二区熟女人妻| 亚洲av中文字字幕乱码综合| 亚洲,欧美,日韩| 在线a可以看的网站| 你懂的网址亚洲精品在线观看 | 听说在线观看完整版免费高清| 亚洲av第一区精品v没综合| 好男人在线观看高清免费视频| 久久久国产成人精品二区| 午夜福利成人在线免费观看| 成人性生交大片免费视频hd| 久久人人爽人人片av| 欧洲精品卡2卡3卡4卡5卡区| 美女被艹到高潮喷水动态| 亚洲无线观看免费| 人人妻人人看人人澡| 赤兔流量卡办理| 久久久久免费精品人妻一区二区| 欧美日韩国产亚洲二区| 黄色配什么色好看| 国产熟女欧美一区二区| 亚洲欧美精品自产自拍| 亚洲激情五月婷婷啪啪| 男女啪啪激烈高潮av片| 日本免费一区二区三区高清不卡| 国产成人91sexporn| 欧美性猛交黑人性爽| 综合色av麻豆| 欧美在线一区亚洲| 在线观看午夜福利视频| 午夜福利视频1000在线观看| av女优亚洲男人天堂| 精品人妻熟女av久视频| 亚洲成a人片在线一区二区| 中出人妻视频一区二区| 在线免费观看不下载黄p国产| 国产人妻一区二区三区在| 亚洲欧美日韩卡通动漫| 麻豆成人午夜福利视频| 亚洲一区高清亚洲精品| 亚洲在线观看片| 男女那种视频在线观看| 亚洲在线自拍视频| 国产成人精品一,二区 | 在线播放国产精品三级| 99久久精品一区二区三区| 一级黄色大片毛片| 深夜a级毛片| 国产伦精品一区二区三区视频9| 国产高清激情床上av| 国产精品,欧美在线| av在线播放精品| 日本撒尿小便嘘嘘汇集6| 精品国内亚洲2022精品成人| 日韩成人伦理影院| 亚洲三级黄色毛片| 99久久精品一区二区三区| 中国美白少妇内射xxxbb| 亚洲中文字幕一区二区三区有码在线看| 自拍偷自拍亚洲精品老妇| 99久久精品热视频| 最近视频中文字幕2019在线8| 国产成人freesex在线| av.在线天堂| 2022亚洲国产成人精品| 日日撸夜夜添| 性插视频无遮挡在线免费观看| 日本撒尿小便嘘嘘汇集6| 青春草视频在线免费观看| 一级黄色大片毛片| 国产女主播在线喷水免费视频网站 | 亚洲精品自拍成人| 少妇被粗大猛烈的视频| 一区福利在线观看| 中文精品一卡2卡3卡4更新| 黄色视频,在线免费观看| 国产精品一区二区三区四区久久| 狂野欧美激情性xxxx在线观看| 岛国在线免费视频观看| 亚洲四区av| 啦啦啦啦在线视频资源| 成人综合一区亚洲| a级一级毛片免费在线观看| 国产极品精品免费视频能看的| 久久精品国产自在天天线| 我的女老师完整版在线观看| 久久人人爽人人爽人人片va| 国产黄a三级三级三级人| 久久久久久久久久黄片| 久久综合国产亚洲精品| 色综合站精品国产| 日韩成人av中文字幕在线观看| 日日干狠狠操夜夜爽| 男人的好看免费观看在线视频| 99热全是精品| 午夜福利成人在线免费观看| 大又大粗又爽又黄少妇毛片口| 久久久久久久久久成人| 免费av不卡在线播放| 欧美日韩在线观看h| 97在线视频观看| 国模一区二区三区四区视频| 亚洲国产精品久久男人天堂| 成熟少妇高潮喷水视频| 亚洲美女搞黄在线观看| 亚洲一区高清亚洲精品| 国产老妇伦熟女老妇高清| 中文资源天堂在线| 国产成人91sexporn| 51国产日韩欧美| 欧美激情国产日韩精品一区| 国产高潮美女av| 国产私拍福利视频在线观看| 亚洲综合色惰| 五月玫瑰六月丁香| 欧美色视频一区免费| 亚洲在线观看片| 成人亚洲精品av一区二区| 亚洲成av人片在线播放无| 波多野结衣巨乳人妻| 成人高潮视频无遮挡免费网站| 又粗又爽又猛毛片免费看| 亚洲国产欧美在线一区| 日本一二三区视频观看| 午夜精品国产一区二区电影 | 久99久视频精品免费| 国产探花极品一区二区| 精品久久国产蜜桃| 特大巨黑吊av在线直播| 精品熟女少妇av免费看| 国产精品精品国产色婷婷| 国产成人精品一,二区 | 欧美色视频一区免费| 日韩一区二区视频免费看| 欧美bdsm另类| 国产人妻一区二区三区在| 精品少妇黑人巨大在线播放 | 一区二区三区高清视频在线| 日韩av在线大香蕉| 日韩一区二区视频免费看| 婷婷六月久久综合丁香| 国产69精品久久久久777片| 日本-黄色视频高清免费观看| 国产一区二区激情短视频| 99久久精品国产国产毛片| 91精品国产九色| 亚洲成人av在线免费| 长腿黑丝高跟| 男人狂女人下面高潮的视频| 成人亚洲欧美一区二区av| 久久精品综合一区二区三区| 欧美极品一区二区三区四区| 日本黄大片高清| 国产黄色小视频在线观看| 99久久成人亚洲精品观看| 麻豆久久精品国产亚洲av| 日本爱情动作片www.在线观看| 可以在线观看毛片的网站| 菩萨蛮人人尽说江南好唐韦庄 | 精品人妻视频免费看| 日韩中字成人| 亚洲欧美中文字幕日韩二区| 少妇高潮的动态图| 久久人人爽人人爽人人片va| 色尼玛亚洲综合影院| 天天躁夜夜躁狠狠久久av| 久久韩国三级中文字幕| 97超碰精品成人国产| av免费在线看不卡| 色视频www国产| 国内精品美女久久久久久| 亚洲欧美日韩卡通动漫| 18+在线观看网站| 日日撸夜夜添| 免费看日本二区| 日韩欧美 国产精品| 欧美日韩乱码在线| 在线播放国产精品三级| 日韩欧美 国产精品| 免费搜索国产男女视频| 97超碰精品成人国产| 国产精品一区二区三区四区久久| 蜜桃久久精品国产亚洲av| 亚洲真实伦在线观看| 午夜精品在线福利| www.av在线官网国产| 深夜精品福利| 久久99热6这里只有精品| 国产熟女欧美一区二区| 国产黄色小视频在线观看| 人妻系列 视频| 岛国毛片在线播放| 国产一区二区激情短视频| 丝袜喷水一区| 国产成人91sexporn| 亚洲人成网站在线播| 亚洲自拍偷在线| 国产中年淑女户外野战色| 悠悠久久av| 午夜福利在线观看吧| 国产精品99久久久久久久久| 久久久久久大精品| 精品久久久久久久久久久久久| 亚洲欧美精品自产自拍| 中国美女看黄片| 最近最新中文字幕大全电影3| 亚洲中文字幕日韩| 国产高清有码在线观看视频| 日韩成人伦理影院| 国产精品三级大全| 日本一本二区三区精品| 丰满的人妻完整版| 国产av一区在线观看免费| 亚洲成人精品中文字幕电影| 简卡轻食公司| h日本视频在线播放| 舔av片在线| 99热精品在线国产| 久久久久久伊人网av| 蜜桃亚洲精品一区二区三区| 大型黄色视频在线免费观看| 午夜老司机福利剧场| 两性午夜刺激爽爽歪歪视频在线观看| 又粗又硬又长又爽又黄的视频 | 99热精品在线国产| 国产蜜桃级精品一区二区三区| 久久精品久久久久久久性| 夜夜看夜夜爽夜夜摸| 久久6这里有精品| 色5月婷婷丁香| 欧美性猛交╳xxx乱大交人| 欧美激情久久久久久爽电影| 日韩制服骚丝袜av| 最近的中文字幕免费完整| av福利片在线观看| 欧美日韩乱码在线| 国产精品野战在线观看| 精品一区二区免费观看| 欧美丝袜亚洲另类| 色综合色国产| 听说在线观看完整版免费高清| 久久久久久久亚洲中文字幕| 欧美日韩在线观看h| 亚洲国产色片| 我的老师免费观看完整版| 久久久色成人| 国产爱豆传媒在线观看| 在线免费观看不下载黄p国产| 国产亚洲5aaaaa淫片| 免费看日本二区| 午夜a级毛片| 国产精品久久电影中文字幕| 日韩欧美一区二区三区在线观看| 欧美3d第一页| 3wmmmm亚洲av在线观看| 校园春色视频在线观看| 看非洲黑人一级黄片| 国产精品永久免费网站| 国产蜜桃级精品一区二区三区| 国产色爽女视频免费观看| 国产成年人精品一区二区| 99热这里只有是精品50| 久久精品久久久久久噜噜老黄 | 舔av片在线| 欧美最黄视频在线播放免费| 少妇被粗大猛烈的视频| 麻豆乱淫一区二区| 天堂中文最新版在线下载 | 伊人久久精品亚洲午夜| 亚洲最大成人av| 99热这里只有是精品50| 美女大奶头视频| 少妇熟女欧美另类| 亚洲电影在线观看av| 黄色视频,在线免费观看| 校园春色视频在线观看| 亚洲电影在线观看av| 国产精品日韩av在线免费观看| 男人狂女人下面高潮的视频| 三级国产精品欧美在线观看| 69人妻影院| 小蜜桃在线观看免费完整版高清| 18禁黄网站禁片免费观看直播| 国产黄色视频一区二区在线观看 | 真实男女啪啪啪动态图| 欧美日韩精品成人综合77777| 久久久国产成人免费| 一级黄色大片毛片| 亚洲欧美日韩卡通动漫| 尾随美女入室| 国国产精品蜜臀av免费| 老师上课跳d突然被开到最大视频| 亚洲精品成人久久久久久| 在现免费观看毛片| 天天躁夜夜躁狠狠久久av| 久久久国产成人精品二区| 男女下面进入的视频免费午夜| 午夜久久久久精精品| 亚洲国产欧美在线一区| 一级毛片aaaaaa免费看小| a级毛片a级免费在线| 亚洲,欧美,日韩| 美女内射精品一级片tv| 欧美日韩一区二区视频在线观看视频在线 | 亚洲自拍偷在线| 亚洲不卡免费看| 欧美bdsm另类| 亚洲人成网站高清观看| 亚洲无线在线观看| 国产免费男女视频| 日日干狠狠操夜夜爽| 国产亚洲精品av在线| 亚洲欧洲日产国产| 波多野结衣巨乳人妻| 乱人视频在线观看| 岛国毛片在线播放| 18禁在线无遮挡免费观看视频| 你懂的网址亚洲精品在线观看 | 一本久久精品| 亚洲欧美精品自产自拍| 亚洲欧美中文字幕日韩二区| 日韩人妻高清精品专区| 国产v大片淫在线免费观看|